Truffle Capital Raises €250M For New BioMedtech VC Fund
French VC firm Truffle Capital has raised €250 million ($278m) for its new BioMedTech fund. The capital will be used to create 12 new medtech companies.
You may also be interested in...
French Start-Up Seals Deal For Harvard's Tissue Repair Tech
HoliStick Medical has gained a worldwide exclusive license from Harvard University for a catheter-based tool to repair tissue defects in difficult-to-reach organs.
Truffle Eyes A Dozen Investments With New BioMedtech Fund
Truffle Capital has raised $102m for its new institutional venture fund, nearly half of its $240m target, and is set to create and finance a dozen biotech and medtech companies with the capital.
Stryker's Deal For Spine Device Maker Vexim Rounds Up Ortho M&A Trilogy
It's been a busy week for ortho M&A activity, with three key sector players cutting deals. Smith & Nephew's agreement to buy Rotation Medical kick-started the week, then two more deals followed in succession, with Exactech announcing it was to be acquired by private equity firm TPG Capital and Stryker saying it will acquire a majority control of Vexim, a French spinal device maker.